Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well erlotinib works in treating patients with locally
advanced or metastatic papillary renal cell (kidney) cancer. Erlotinib may stop the growth of
tumor cells by blocking the enzymes necessary for tumor cell growth